MEDNAX Inc (NYSE:MD) – Equities research analysts at William Blair lifted their Q2 2018 earnings estimates for shares of MEDNAX in a research report issued to clients and investors on Tuesday. William Blair analyst R. Daniels now forecasts that the company will earn $0.97 per share for the quarter, up from their previous forecast of $0.94.
MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.04. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The company had revenue of $910.82 million during the quarter, compared to analyst estimates of $884.55 million. During the same quarter last year, the firm posted $1.00 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis.
Other equities analysts have also issued research reports about the stock. KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research report on Wednesday, November 1st. Stephens set a $62.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research raised shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Tuesday, January 23rd. SunTrust Banks set a $55.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, December 21st. Finally, Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $54.92.
MEDNAX (MD) opened at $56.43 on Wednesday. MEDNAX has a 12-month low of $40.56 and a 12-month high of $72.13. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a market cap of $5,309.77, a PE ratio of 18.03, a PEG ratio of 1.40 and a beta of 0.31.
Institutional investors have recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of MEDNAX in the third quarter worth $103,000. Denali Advisors LLC acquired a new stake in shares of MEDNAX in the third quarter worth $185,000. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of MEDNAX by 45.3% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock worth $226,000 after acquiring an additional 1,630 shares during the last quarter. Delta Capital Management LLC acquired a new stake in shares of MEDNAX in the fourth quarter worth $227,000. Finally, Brown Advisory Inc. acquired a new stake in shares of MEDNAX in the fourth quarter worth $231,000. Institutional investors and hedge funds own 95.12% of the company’s stock.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MEDNAX Inc to Post Q2 2018 Earnings of $0.97 Per Share, William Blair Forecasts (MD)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/02/21/mednax-inc-to-post-q2-2018-earnings-of-0-97-per-share-william-blair-forecasts-md.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.